The editorial discusses the meta-analysis by Ciria et al., which evaluates liver transplantation (LT) as a curative treatment for nonstandard oncological indications, including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, neuroendocrine tumor liver metastases, and colorectal liver metastases. The study employs a robust methodology, combining individual participant data meta-analyses with pooled data, and applies oncological selection criteria to ensure relevance for clinical practice. While the findings suggest that LT may offer survival benefits for select oncological cases, limitations include the heterogeneity of malignancies analyzed and the lower survival rates compared to conventional LT indications. This editorial underscores the need for further prospective studies and randomized trials to refine selection criteria and validate long-term outcomes.